News Releases
- May 11, 2021Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
- May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange
- May 6, 2021Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
- April 29, 2021Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
- April 15, 2021Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
- March 17, 2021Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
- March 16, 2021Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
- March 11, 2021Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
- March 11, 2021Annovis Bio, Inc. to present at the Q1 Virtual Investor SummitÂ
- March 10, 2021Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top